Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction.
Authors:
Journal: Cardiovascular research
Publication Type: Journal Article
Date: 2020
DOI: PMC7061278
ID: 31710673
Abstract
Early mechanical reperfusion of the epicardial coronary artery by primary percutaneous coronary intervention (PCI) is the guideline-recommended treatment for ST-elevation myocardial infarction (STEMI). Successful restoration of epicardial coronary blood flow can be achieved in over 95% of PCI procedures. However, despite angiographically complete epicardial coronary artery patency, in about half of the patients perfusion to the distal coronary microvasculature is not fully restored, which is associated with increased morbidity and mortality. The exact pathophysiological mechanism of post-ischaemic coronary microvascular dysfunction (CMD) is still debated. Therefore, the current review discusses invasive and non-invasive techniques for the diagnosis and quantification of CMD in STEMI in the clinical setting as well as results from experimental in vitro and in vivo models focusing on ischaemic-, reperfusion-, and inflammatory damage to the coronary microvascular endothelial cells. Finally, we discuss future opportunities to prevent or treat CMD in STEMI patients.
Reference List
- Cohen M, Boiangiu C, Abidi M.. Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy. J Am Coll Cardiol 2010;55:1895–1906.|||Van Kranenburg MV, Magro M, Thiele H, DeWaha S, Eitel I, Cochet A, Cottin Y, Atar D, Buser P, Wu E, Lee D, Bodi V, Klug G, Metzler B, Delewi R, Bernhardt P, Rottbauer W, Boersma E, Zijlstra F, Geuns RJ.. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging 2014;7:930–939.|||Reffelmann T, Kloner RA.. Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am J Physiol Circ Physiol 2002;283:H1099–H1107.|||Lima JAC, Wu KC, Becker LC, Melin JA, Gerber BL, Rochitte CE, Bluemke DA, McVeigh ER.. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2012;101:2734–2741.|||Kloner RA, Ganote CE, Jennings RB.. The ‘no reflow’ phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496–1508.|||Sezer M, van Royen N, Umman B, Bugra Z, Bulluck H, Hausenloy DJ, Umman S.. Coronary microvascular injury in reperfused acute myocardial infarction: a view from an integrative perspective. J Am Heart Assoc 2018;7:1–16.|||Heusch G. Critical issues for the translation of cardioprotection. Circ Res 2017;120:1477–1486.|||Hausenloy DJ, Chilian W, Crea F, Davidson SM, Ferdinandy P, Garcia-Dorado D, van RN, Schulz R, Heusch G.. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res 2019;115:1143–1155.|||Bulluck H, Yellon DM, Hausenloy DJ.. Reducing myocardial infarct size: challenges and future opportunities. Heart 2016;102:341–348.|||Krug A, Mesnil de Rochemont D, Korb G.. Blood supply of the myocardium after temporary coronary occlusion. Circ Res 1966;19:57–62.|||Ames A, Wright RL, Kowada M, Thurston JM, Majno G.. Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol 1968;52:437–453.|||Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther 2011;16:244–250.|||Schofer J, Montz R, Mathey DG.. Scintigraphic evidence of the “No reflow” phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol 1985;5:593–598.|||Bates ER, Krell MJ, Dean EN, O'Neill WW, Vogel RA.. Demonstration of the “no-reflow” phenomenon by digital coronary arteriography. Am J Cardiol 1986;57:177–178.|||Feld H, Lichstein E, Schachter J, Shani J.. Early and late angiographic findings of the ‘no-reflow’ phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992;123:782–784.|||Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, Wang TY.. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013;111:178–184.|||McCartney PJ, Eteiba H, Maznyczka AM, McEntegart M, Greenwood JP, Muir DF, Chowdhary S, Gershlick AH, Appleby C, Cotton JM, Wragg A, Curzen N, Oldroyd KG, Lindsay M, Rocchiccioli JP, Shaukat A, Good R, Watkins S, Robertson K, Malkin C, Martin L, Gillespie L, Ford TJ, Petrie MC, Macfarlane PW, Tait RC, Welsh P, Sattar N, Weir RA, Fox KA, Ford I, McConnachie A, Berry C.. Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial. JAMA 2019;321:56–68.|||Carrick D, Haig C, Ahmed N, Rauhalammi S, Clerfond G, Carberry J, Mordi I, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay M, Mahrous A, Welsh P, Sattar N, Ford I, Oldroyd KG, Radjenovic A, Berry C.. Temporal evolution of myocardial hemorrhage and edema in patients after acute ST-segment elevation myocardial infarction: pathophysiological insights and clinical implications. J Am Heart Assoc 2016;5:1–13.|||Van Robbers L, Eerenberg ES, Teunissen PF, Jansen MF, Hollander MR, Horrevoets AJG, Knaapen P, Nijveldt R, Heymans MW, Levi MM, Rossum AC, Van Niessen HWM, Marcu CB, Beek AM, Royen N.. Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage. Eur Heart J 2013;34:2346–2353.|||Van Den Bos BE, Baks T, Moelker AD, Kerver W, Geuns RV, Giessen WJ, Van Der Duncker DJ, Wielopolski PA.. Magnetic resonance imaging of haemorrhage within reperfused myocardial infarcts: possible interference with iron oxide-labelled cell tracking? Eur Heart J 2006;27:1620–1626.|||Betgem RP, Waard GD, Nijveldt R, Beek AM, Escaned J, Van Royen N.. Intramyocardial haemorrhage after acute myocardial infarction. Nat Rev Cardiol 2015;12:156–167.|||Roberts CS, Schoen FJ, Kloner RA.. Effect of coronary reperfusion on myocardial hemorrhage and infarct healing. Am J Cardiol 1983;52:610–614.|||Hollander MR, Waard G. D, Konijnenberg LSF, Meijer-van Putten RME, Brom C. V D, Paauw N, Vries H. D, Ven P. V D, Aman J, Nieuw-Amerongen GV, Hordijk PL, Niessen HWM, Horrevoets AJG, Royen NV.. Dissecting the effects of ischemia and reperfusion on the coronary microcirculation in a rat model of acute myocardial infarction. PLoS One 2016;11:e0157233..|||Waha SD, Desch S, Eitel I, Fuernau G, Zachrau J, Leuschner A, Gutberlet M, Schuler G, Thiele H.. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. Eur Heart J 2010;31:2660–2668.|||Husser O, Monmeneu JV, Sanchis J, Nunez J, Lopez-Lereu MP, Bonanad C, Chaustre F, Gomez C, Bosch MJ, Hinarejos R, Chorro FJ, Riegger GAJ, Llacer A, Bodi V.. Cardiovascular magnetic resonance-derived intramyocardial hemorrhage after STEMI: influence on long-term prognosis, adverse left ventricular remodeling and relationship with microvascular obstruction. Int J Cardiol 2013;167:2047–2054.|||TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engel J Med 1985;312:932–936.|||Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, Boura J, O'Neill W, Grines CL.. Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1739–1746.|||Caixeta A, Lansky AJ, Mehran R, Brener SJ, Claessen B, Genereux P, Palmerini T, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Fahy M, Dangas GD, Stone GW.. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. Eurointervention 2013;9:220–227.|||Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MBM, Umans V, Algra PR, Twisk JWR, van Rossum AC.. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol 2008;52:181–189.|||Kunadian V, Harrigan C, Zorkun C, Palmer AM, Ogando KJ, Biller LH, Lord EE, Williams SP, Lew ME, Ciaglo LN, Buros JL, Marble SJ, Gibson WJ, Gibson CM.. Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years. J Thromb Thrombolysis 2009;27:316–328.|||Abaci A, Oguzhan A, Eryol NK, Ergin A.. Effect of potential confounding factors on the thrombolysis in myocardial infarction (TIMI) trial frame count and its reproducibility. Circulation 1999;100:2219–2223.|||French JK, Ellis CJ, Webber BJ, Williams BF, Amos DJ, Ramanathan K, Whitlock RM, White HD.. Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected thrombolysis in myocardial infarction (TIMI) frame count and stenosis severity. Am J Cardiol 1998;81:665–671.|||Gibson CM, Murphy SA, Rizzo MJ, Ryan K. A, Marble SJ, McCabe CH, Cannon CP, Van de Werf F, Braunwald E.. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation 1999;99:1945–1950.|||Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E.. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002;105:1909–1913.|||Bhatt DL, Ellis SG, Ivanc TB, Crowe T, Balazs E, Debowey D, Pangerl A, Chew PH.. Corrected TIMI frame count does not predict 30-day adverse outcomes after reperfusion therapy for acute myocardial infarction. Am Heart J 1999;138:785–790.|||Haager PK, Christott P, Heussen N, Lepper W, Hanrath P, Hoffmann R.. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion. J Am Coll Cardiol 2003;41:532–538.|||van’T Hof AW, Liem A, Suryapranata H, Hoorntje JCA, de Boer M-J, Zijlstra F.. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction—myocardial blush grade. Circulation 1998;97:2302–2306.|||Marra MP, Corbetti F, Cacciavillani L, Tarantini G, Ramondo AB, Napodano M, Basso C, Lacognata C, Marzari A, Maddalena F, Iliceto S.. Relationship between myocardial blush grades, staining, and severe microvascular damage after primary percutaneous coronary intervention: a study performed with contrast-enhanced magnetic resonance in a large consecutive series of patients. Am Heart J 2010;159:1124–1132.|||Vogelzang M, Vlaar PJ, Svilaas T, Amo D, Nijsten MWN, Zijlstra F.. Computer-assisted myocardial blush quantification after percutaneous coronary angioplasty for acute myocardial infarction: a substudy from the TAPAS trial. Eur Heart J 2009;30:594–599.|||Haeck JDE, Gu YL, Vogelzang M, Bilodeau L, Krucoff MW, Tijssen JGP, Winter RD, Zijlstra F, Koch KT.. Feasibility and applicability of computer-assisted myocardial blush quantification after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Catheter Cardiovasc Interv 2010;75:701–706.|||Biesbroek PS, Roos ST, Hout MV, Gragt JVD, Teunissen PFA, Waard GD, Knaapen P, Kamp O, Royen NV.. Fluoroscopy assisted scoring of myocardial hypoperfusion (FLASH) ratio as a novel predictor of mortality after primary PCI in STEMI patients. Int J Cardiol 2016;202:639–645.|||Everaars H, de Waard GA, Driessen RS, Danad I, Van de Ven PM, Raijmakers PG, Lammertsma AA, van Rossum AC, Knaapen P, van Royen N.. Doppler flow velocity and thermodilution to assess coronary flow reserve: a head-to-head comparison with [15O]H2O PET. JACC Cardiovasc Interv 2018;11:2044–2054.|||Carrick D, Haig C, Carberry J, May VTY, McCartney P, Welsh P, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Hood S, Watkins S, Mahrous A, Rauhalammi SMO, Mordi I, Ford I, Radjenovic A, Sattar N, Oldroyd KG, Berry C.. Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. JCI Insight 2016;1:1–18.|||Hirsch A, Nijveldt R, Haeck JDE, Beek AM, Koch KT, Henriques JPS, van der Schaaf RJ, Vis MM, Baan J, de Winter R, Tijssen JGP, van Rossum A, Piek JJ.. Relation between the assessment of microvascular injury by cardiovascular magnetic resonance and coronary Doppler flow velocity measurements in patients with acute anterior wall myocardial infarction. J Am Coll Cardiol 2008;51:2230–2238.|||Bulluck H, Foin N, Tan JW, Low AF, Sezer M, Hausenloy DJ.. Invasive assessment of the coronary microcirculation in reperfused ST-segment-elevation myocardial infarction patients: where do we stand? Circ Cardiovasc Interv 2017;10:1–11.|||Hoef TVD, Bax M, Meuwissen M, Damman P, Delewi R, Winter RD, Koch KT, Schotborgh C, Henriques JPS, Tijssen JGP, Piek JJ.. Impact of coronary microvascular function on long-term cardiac mortality in patients with acute ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2013;6:207–215.|||Fearon WF. Invasive coronary physiology for assessing intermediate lesions. Circ Cardiovasc Interv 2015;8:1–8.|||Aarnoudse W, Fearon WF, Manoharan G, Geven M, Vosse FVD, Rutten M, Bruyne BD, Pijls N.. Epicardial stenosis severity does not affect minimal microcirculatory resistance. Circulation 2004;110:2137–2142.|||Bulluck H, Foin N, Cabrera-Fuentes HA, Yeo KK, Wong AS, Fam JM, Wong PE, Tan JW, Low AF, Hausenloy DJ.. Index of microvascular resistance and microvascular obstruction in patients with acute myocardial infarction. JACC Cardiovasc Interv 2016;9:2172–2174.|||Carrick D, Haig C, Ahmed N, Carberry J, Yue May VT, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Hood S, Watkins S, Davie A, Mahrous A, Mordi I, Ford I, Radjenovic A, Oldroyd KG, Berry C.. Comparative prognostic utility of indexes of microvascular function alone or in combination in patients with an acute ST-segment-elevation myocardial infarction. Circulation 2016;134:1833–1847.|||Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim HS, Loh JP, Oldroyd KG.. Prognostic value of the index of microcirculatory resistance measured after primary percutaneous coronary intervention William. Circulation 2013;127:2436–2441.|||Teunissen PFA, Waard GD, Hollander MR, Robbers L, Danad I, Biesbroek PS, Amier RP, Echavarría-Pinto M, Quirós A, Broyd C, Heymans MW, Nijveldt R, Lammertsma AA, Raijmakers PG, Allaart CP, Lemkes JS, Appelman YE, Marques KM, Bronzwaer JGF, Horrevoets AJG, Rossum AV, Escaned J, Beek AM, Knaapen P, Royen NV.. Doppler-derived intracoronary physiology indices predict the occurrence of microvascular injury and microvascular perfusion deficits after angiographically successful primary percutaneous coronary intervention. Circ Cardiovasc Interv 2015;8:1–11.|||Jin XJ, Yoon MH, Seo KW, Tahk SJ, Lim HS, Yang HM, Choi BJ, Choi SY, Hwang GS, Shin JH, Park JS.. Usefulness of hyperemic microvascular resistance index as a predictor of clinical outcomes in patients with ST-segment elevation myocardial infarction. Korean Circ J 2015;45:194–201.|||Hennigan B, Layland J, Fearon WF, Oldroyd KG.. Fractional flow reserve and the index of microvascular resistance in patients with acute coronary syndromes. Eurointervention 2014;10(Suppl. T):T55–63.|||Layland J, Carrick D, McEntegart M, Ahmed N, Payne A, McClure J, Sood A, McGeoch R, MacIsaac A, Whitbourn R, Wilson A, Oldroyd K, Berry C.. Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2013;6:231–236.|||Xaplanteris P, Fournier S, Keulards DCJ, Adjedj J, Ciccarelli G, Milkas A, Pellicano M, van’t Veer M, Barbato E, Pijls NHJ, Bruyne BD.. Catheter-based measurements of absolute coronary blood flow and microvascular resistance. Circ Cardiovasc Interv 2018;11:1–8.|||Wijnbergen I, van't Veer M, Lammers J, Ubachs J, Pijls NHJ.. Absolute coronary blood flow measurement and microvascular resistance in ST-elevation myocardial infarction in the acute and subacute phase. Cardiovasc Revasc Med 2016;17:81–87.|||Escaned J, Flores A, García-Pavía P, Segovia J, Jimenez J, Aragoncillo P, Salas C, Alfonso F, Hernández R, Angiolillo DJ, Jiménez-Quevedo P, Bañuelos C, Alonso-Pulpón L, Macaya C.. Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements. Circulation 2009;120:1561–1568.|||Shibata T, Watanabe H, Tsurusaki T, Minai K, Ogawa T, Iwano K, Tamura T, Yoshida S, Mutou M, Imai K, Horie T, Mochizuki S.. Do indices of coronary conductance after reperfusion reflect the extent of salvaged myocardium? Jpn Heart J 2004;45:387–396.|||Shimada K, Sakanoue Y, Kobayashi Y, Ehara S, Hirose M, Nakamura Y, Fukuda D, Yamagishi H, Yoshiyama M, Takeuchi K, Yoshikawa J.. Assessment of myocardial viability: using coronary pressure and flow after acute myocardial infarction. Heart 2003;89:71–76.|||Bellamy RF. Diastolic coronary artery pressure-flow relations in the dog. Circ Res 1978;43:92–101.|||Herck PV, Carlier SG, Claeys MJ, Haine SE, Gorissen P, Miljoen H, Bosnians JM, Vrints CJ.. Coronary microvascular dysfunction after myocardial infarction: increased coronary zero flow pressure both in the infarcted and in the remote myocardium is mainly related to left ventricular filling pressure. Heart 2007;93:1231–1237.|||Kitabata H, Imanishi T, Kubo T, Takarada S, Kashiwagi M, Matsumoto H, Tsujioka H, Ikejima H, Arita Y, Okochi K, Kuroi A, Ueno S, Kataiwa H, Tanimoto T, Yamano T, Hirata K, Nakamura N, Tanaka A, Mizukoshi M, Akasaka T.. Coronary microvascular resistance index immediately after primary percutaneous coronary intervention as a predictor of the transmural extent of infarction in patients with ST-segment elevation anterior acute myocardial infarction. JACC Cardiovasc Imaging 2009;2:263–272.|||Patel N, Petraco R, Dall’Armellina E, Kassimis G, Maria GD, Dawkins S, Lee R, Prendergast BD, Choudhury RP, Forfar JC, Channon KM, Davies J, Banning AP, Kharbanda RK.. Zero-flow pressure measured immediately after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction provides the best invasive index for predicting the extent of myocardial infarction at 6 months: an OxAMI study (Oxford Acute Myocardial Infarction). JACC Cardiovasc Interv 2015;8:1410–1421.|||Kim RJ, Fieno DS, Parrish TB, Harris K, Chen E, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM.. Irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992–2002.|||Nijveldt R, Hofman MBM, Hirsch A, Beek AM, Umans V, Algra PR, Piek JJ, van Rossum AC.. Assessment of microvascular obstruction and prediction of short-term remodeling after acute myocardial infarction: cardiac MR imaging study. Radiology 2009;250:363–370.|||Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, Bucciarelli-Ducci C, Croisille P, Dall'Armellina E, Dharmakumar R, Eitel I, Fernández-Jiménez R, Friedrich MG, García-Dorado D, Hausenloy DJ, Kim RJ, Kozerke S, Kramer CM, Salerno M, Sánchez-González J, Sanz J, Fuster V.. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. J Am Coll Cardiol 2019;74:238–256.|||Demirkiran A, Everaars H, Amier RP, Beijnink C, Bom MJ, Götte MJW, van Loon R, Selder JL, van Rossum A, Nijveldt R.. Cardiovascular magnetic resonance techniques for tissue characterization after acute myocardial injury. Eur Heart J Cardiovasc Imaging 2019;20:723–734.|||Beek AM, Nijveldt R, Rossum AV.. Intramyocardial hemorrhage and microvascular obstruction after primary percutaneous coronary intervention. Int J Cardiovasc Imaging 2010;26:49–55.|||Basso C, Corbetti F, Silva C, Abudureheman A, Lacognata C, Cacciavillani L, Tarantini G, Marra MP, Ramondo A, Thiene G, Iliceto S.. Morphologic validation of reperfused hemorrhagic myocardial infarction by cardiovascular magnetic resonance. Am J Cardiol 2007;100:1322–1327.|||Kumar A, Green JD, Sykes JM, Ephrat P, Carson JJL, Mitchell AJ, Wisenberg G, Friedrich MG.. Detection and quantification of myocardial reperfusion hemorrhage using T2 (*)-weighted CMR. JACC Cardiovasc Imaging 2011;4:1274–1283.|||Baldea I, Teacoe I, Olteanu DE, Vaida-Voievod C, Clichici A, Sirbu A, Filip GA, Clichici S.. Effects of different hypoxia degrees on endothelial cell cultures—time course study. Mech Ageing Dev 2018;172:45–50.|||Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, Kay M, Winn R, Harlan J.. Mechanisms of hypoxia-induced endothelial cell death. J Biol Chem 1999;274:8039–8045.|||Faller DV. Endothelial cell responses to hypoxic stress. Experimental biology 1998 symposium on molecular approaches to understanding cellular responses to stress. Clin Exp Pharmacol Physiol 1999;26:74–84.|||Tsao PS, Aoki N, Lefer DJ, Johnson G, Lefer AM.. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990;82:1402–1412.|||Viehman GE, Ma XL, Lefer DJ, Lefer AM.. Time course of endothelial dysfunction and myocardial injury during coronary arterial occlusion. Am J Physiol Circ Physiol 1991;261:H874–H881.|||VanBenthuysen KM, McMurtry IF, Horwitz LD.. Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro. J Clin Invest 1987;79:265–274.|||Ma X, Zhang H, Pan Q, Zhao Y, Chen J, Zhao B, Chen Y.. Hypoxia/aglycemia-induced endothelial barrier dysfunction and tight junction protein downregulation can be ameliorated by citicoline. PLoS One 2013;8:e82604.|||Funamoto K, Yoshino D, Matsubara K, Zervantonakis IK, Funamoto K, Nakayama M, Masamune J, Kimura Y, Kamm RD.. Endothelial monolayer permeability under controlled oxygen tension. Integr Biol 2017;9:529–538.|||Gavin JB, Seelye RN, Nevalainen TJ, Armiger LC.. The effect of ischaemia on the function and fine structure of the microvasculature of myocardium. Pathology 1978;10:103–111.|||Kloner RA, Rude RE, Carlson N, Maroko PR, DeBoer LW, Braunwald E.. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation 1980;62:945–952.|||Fernández-Jiménez R, Galán-Arriola C, Sánchez-González J, Agüero J, López-Martín GJ, Gomez-Talavera S, Garcia-Prieto J, Benn A, Molina-Iracheta A, Barreiro-Pérez M, Martin-García A, García-Lunar I, Pizarro G, Sanz J, Sánchez PL, Fuster V, Ibanez B.. Effect of ischemia duration and protective interventions on the temporal dynamics of tissue composition after myocardial infarction. Circ Res 2017;121:439–450.|||Ghugre NR, Pop M, Barry J, Connelly KA, Wright GA.. Quantitative magnetic resonance imaging can distinguish remodeling mechanisms after acute myocardial infarction based on the severity of ischemic insult. Magn Reson Med 2013;70:1095–1105.|||Nevalainen T, Armiger LC, Gavin JB.. Effects of ischaemia on vasculature. J Mol Cell Cardiol 1986;18(Suppl. 4):7–10.|||Reffelmann T, Hale SL, Li G, Kloner RA.. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Circ Physiol 2002;282:H766–H772.|||Yu H, Kalogeris T, Korthuis RJ.. Reactive species-induced microvascular dysfunction in ischemia/reperfusion. Free Radic Biol Med 2019;135:182–197.|||Rodrigo R, Libuy M, Feliú F, Hasson D.. Molecular basis of cardioprotective effect of antioxidant vitamins in myocardial infarction. Biomed Res Int 2013;2013:1–15.|||Qin C, Yap S, Woodman OL. Antioxidants in the prevention of myocardial ischemia/reperfusion injury. Expert Rev Clin Pharmacol 2009;2:673–695.|||Elmoselhi AB, Dhalla NS, Makino N, Hata T.. Status of myocardial antioxidants in ischemia–reperfusion injury. Cardiovasc Res 2000;47:446–456.|||Heusch G. The coronary circulation as a target of cardioprotection. Circ Res 2016;118:1643–1658.|||Garcia-Dorado D, Andres-Villarreal M, Ruiz-Meana M, Inserte J, Barba I.. Myocardial edema: a translational view. J Mol Cell Cardiol 2012;52:931–939.|||Fernández-Jiménez R, García-Prieto J, Sánchez-González J, Agüero J, López-Martín GJ, Galán-Arriola C, Molina-Iracheta A, Doohan R, Fuster V, Ibáñez B.. Pathophysiology underlying the bimodal edema phenomenon after myocardial ischemia/reperfusion. J Am Coll Cardiol 2015;66:816–828.|||Fernández-Jiménez R, Sánchez-González J, Agüero J, García-Prieto J, López-Martín GJ, García-Ruiz JM, Molina-Iracheta A, Rosselló X, Fernández-Friera L, Pizarro G, García-Álvarez A, Dall'Armellina E, Macaya C, Choudhury RP, Fuster V, Ibáñez B.. Myocardial edema after ischemia/reperfusion is not stable and follows a bimodal pattern: imaging and histological tissue characterization. J Am Coll Cardiol 2015;65:315–323.|||Foltz WD, Yang Y, Graham JJ, Detsky JS, Wright GA, Dick AJ.. MRI relaxation fluctuations in acute reperfused hemorrhagic infarction. Magn Reson Med 2006;56:1311–1319.|||Alkhalil M, Borlotti A, Maria GL, De Gaughran L, Langrish J, Lucking A, Ferreira V, Kharbanda RK, Banning AP, Channon KM, Armellina ED, Choudhury RP.. Dynamic changes in injured myocardium, very early after acute myocardial infarction, quantified using T1 mapping cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2018;20:1–10.|||Fernández-Jiménez R, Barreiro-Pérez M, Martin-García A, Sánchez-González J, Agüero J, Galán-Arriola C, García-Prieto J, Díaz-Pelaez E, Vara P, Martinez I, Zamarro I, Garde B, Sanz J, Fuster V, Sánchez PL, Ibanez B.. Dynamic edematous response of the human heart to myocardial infarction. Circulation 2017;136:1288–1300.|||Manciet LH, Poole DC, McDonagh PF, Copeland JG, Mathieu-Costello O.. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am J Physiol Circ Physiol 1994;266:H1541–H1550.|||Kasseckert SA, Schäfer C, Kluger A, Gligorievski D, Tillmann J, Schlüter KD, Noll T, Sauer H, Piper HM, Abdallah Y.. Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation. Cardiovasc Res 2009;83:381–387.|||Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, Mcsharry H, Iwakura A, Yoon Y-S, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheres D.. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004;113:885–894.|||Galaup A, Gomez E, Souktani R, Durand M, Cazes A, Monnot C, Teillon J, Jan S, Le Bouleti C, Briois G, Philippe J, Pons S, Martin V, Assaly R, Bonnin P, Ratajczak P, Janin A, Thurston G, Valenzuela DM, Murphy AJ, Yancopoulos GD, Tissier R, Berdeaux A, Ghaleh B, Germain S.. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 2012;125:140–149.|||Li Y, Yao Y, Li J, Chen Q, Zhang L, Wang QK.. Losartan protects against myocardial ischemia and reperfusion injury via vascular integrity preservation. FASEB J 2019;33:8555–8564.|||Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R.. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833–1839.|||Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL.. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 2002;54:549–558.|||McNamara JJ, Lacro RV, Yee M, Smith GT.. Hemorrhagic infarction and coronary reperfusion. J Thorac Cardiovasc Surg 1981;81:498–501.|||Lotan CS, Pohost GM, Bishop SP, Bouchard A, Cranney GB.. Assessment of postreperfusion myocardial hemorrhage using proton NMR imaging at 1.5 T. Circulation 1992;86:1018–1025.|||Kali A, Kumar A, Cokic I, Tang RLQ, Tsaftaris SA, Friedrich MG, Dharmakumar R.. Chronic manifestation of postreperfusion intramyocardial hemorrhage as regional iron deposition a cardiovascular magnetic resonance study with ex vivo validation. Circ Cardiovasc Imaging 2013;6:218–228.|||Carrick D, Haig C, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay MM, Davie A, Mahrous A, Mordi I, Rauhalammi S, Sattar N, Welsh P, Radjenovic A, Ford I, Oldroyd KG, Berry C.. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging 2016;9:1–10.|||Bulluck H, Rosmini S, Abdel-Gadir A, White SK, Bhuva AN, Treibel TA, Fontana M, Ramlall M, Hamarneh A, Sirker A, Herrey AS, Manisty C, Yellon DM, Kellman P, Moon JC, Hausenloy DJ.. Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling. Circ Cardiovasc Imaging 2016;9:1–10.|||Kloner RA, Giacomelli F, Alker KJ, Hale SL, Matthews R, Bellows S.. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion. Circulation 1991;84:1758–1772.|||Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, Entman M.. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001;103:2181–2187.|||Sheridan FM, Cole PG, Ramage D.. Leukocyte adhesion to the coronary microvasculature during ischemia and reperfusion in an in vivo canine model. Circulation 1996;93:1784–1787.|||Ge L, Zhou X, Ji W-J, Lu R-Y, Zhang Y, Zhang Y-D, Ma Y-Q, Zhao J-H, Li Y-M.. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. Am J Physiol Circ Physiol 2015;308:H500–H509.|||Götz AK, Zahler S, Stumpf P, Welsch U, Becker BF.. Intracoronary formation and retention of micro aggregates of leukocytes and platelets contribute to postischemic myocardial dysfunction. Basic Res Cardiol 2005;100:413–421.|||Lee MJ, Park SD, Kwon SW, Woo SI, Lee MD, Shin SH, Kim DH, Kwan J, Park KS.. Relation between neutrophil-to-lymphocyte ratio and index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2016;118:1323–1328.|||Reindl M, Reinstadler SJ, Feistritzer HJ, Klug G, Tiller C, Mair J, Mayr A, Jaschke W, Metzler B.. Relation of inflammatory markers with myocardial and microvascular injury in patients with reperfused ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2017;6:640–649.|||Laan AM, Van Der Hirsch A, Robbers LF, Nijveldt R, Lommerse I, Delewi R, Vleuten PA, Van Der Biemond BJ, Zwaginga JJ, Giessen WJ, Van Der Zijlstra F, Rossum AC, Van Voermans C, Schoot CE, Van Der Shoot CE, Piek JJ.. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction. Am Heart J 2012;163:57–65.e2.|||Teren A, Kirsten H, Beutner F, Scholz M, Holdt LM, Teupser D, Gutberlet M, Thiery J, Schuler G, Eitel I.. Alteration of multiple leukocyte gene expression networks is linked with magnetic resonance markers of prognosis after acute ST-elevation myocardial infarction. Sci Rep 2017;7:1–10.|||Shetelig C, Limalanathan S, Hoffmann P, Seljeflot I, Gran JM, Eritsland J, Andersen G.. Association of IL-8 with infarct size and clinical outcomes in patients with STEMI. J Am Coll Cardiol 2018;72:187–198.|||Guo F, Dong M, Ren F, Zhang C, Li J, Tao Z, Yang J, Li G.. Association between local interleukin-6 levels and slow flow/microvascular dysfunction. J Thromb Thrombolysis 2014;37:475–482.|||Zeng M, Yan H, Chen Y, Jun ZH, Lv Y, Liu C, Zhou P, Zhao B.. Suppression of NF-κB reduces myocardial no-reflow. PLoS One 2012;7:e47306..|||Yetgin T, Uitterdijk A, Lintel Hekkert M, Merkus D, Te Krabbendam-Peters I, Beusekom HMM, Falotico R, van Serruys PW, Manintveld OC, Geuns R-J, van Zijlstra F, Duncker DJ.. Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration. JACC Cardiovasc Interv 2015;8:1990–1999.|||Uitterdijk A, Yetgin T, Lintel Hekkert M, Te Sneep S, Krabbendam-Peters I, Beusekom HMM, van Fischer TM, Cornelussen RN, Manintveld OC, Merkus D, Duncker DJ.. Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow. Basic Res Cardiol 2015;110:508.|||Rymer JA, Newby LK.. Failure to launch: targeting inflammation in acute coronary syndromes. JACC Basic Transl Sci 2017;2:484–497.|||Faxon DP, Gibbons RJ, Chronos NAF, Gurbel PA, Sheehan F.. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199–1204.|||Ziegler M, Wang X, Peter K.. Platelets in cardiac ischaemia/reperfusion injury : a promising therapeutic target. Cardiovasc Res 2019;115:1178–1188.|||Dijk CGM, Van Nieuweboer FE, Pei JY, Xu YJ, Burgisser P, Mulligen E, Van Azzouzi H, El Duncker DJ, Verhaar MC, Cheng C.. The complex mural cell: pericyte function in health and disease. Int J Cardiol 2015;190:75–89.|||Avolio E, Madeddu P.. Discovering cardiac pericyte biology: from physiopathological mechanisms to potential therapeutic applications in ischemic heart disease. Vascul Pharmacol 2016;86:53–63.|||O’Farrell FM, Attwell D.. A role for pericytes in coronary no-reflow. Nat Rev Cardiol 2014;11:427–432.|||Costa MA, Paiva AE, Andreotti JP, Cardoso MV, Cardoso CD, Mintz A, Birbrair A.. Pericytes constrict blood vessels after myocardial ischemia. J Mol Cell Cardiol 2018;116:1–4.|||Garcia JH, Liu KF, Yoshida Y, Chen S, Lian J.. Brain microvessels: factors altering their patency after the occlusion of a middle cerebral artery (Wistar rat). Am J Pathol 1994;145:728–740.|||Kloner RA, King KS, Harrington MG.. No-reflow phenomenon in the heart and brain. Am J Physiol Circ Physiol 2018;315:H550–H562.|||Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, Molitoris BA.. Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Physiol 2003;285:F191–F198.|||Flores J, DiBona DR, Beck CH, Leaf A.. The role of cell swelling in ischemic renal damage and the protective effect of hypertonic solute. J Clin Invest 1972;51:118–126.|||Khanna A, Rossman JE, Fung HL, Caty MG.. Attenuated nitric oxide synthase activity and protein expression accompany intestinal ischemia/reperfusion injury in rats. Biochem Biophys Res Commun 2000;269:160–164.|||Boros M, Takaichi S, Hatanaka K.. Ischemic time dependent microvascular changes and reperfusion injury in the rat small intestine. J Surg Res 1995;59:311–320.|||Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Lüscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ; WorkingGrouponEndothelinsandEndothelialFactorsof theEuropeanSocietyofHypertension. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233–246.|||Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, Kuroda T, Tanaka K, Masuyama T, Hori M, Fujii K.. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1–7.|||Eitel I, Hintze S, Waha S. D, Fuernau G, Lurz P, Desch S, Schuler G, Thiele H.. Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction: insights from contrast-enhanced magnetic resonance imaging. Circ Cardiovasc Imaging 2012;5:708–718.|||Zia MI, Ghugre NR, Roifman I, Strauss BH, Walcarius R, Mohammed M, Sparkes JD, Dick AJ, Wright GA, Connelly KA.. Comparison of the frequencies of myocardial edema determined by cardiac magnetic resonance in diabetic versus nondiabetic patients having percutaneous coronary intervention for st elevation myocardial infarction. Am J Cardiol 2014;113:607–612.|||Ota S, Tanimoto T, Orii M, Hirata K, Shiono Y, Shimamura K, Matsuo Y, Yamano T, Ino Y, Kitabata H, Yamaguchi T, Kubo T, Tanaka A, Imanishi T, Akasaka T.. Association between hyperglycemia at admission and microvascular obstruction in patients with ST-segment elevation myocardial infarction. J Cardiol 2015;65:272–277.|||Reinstadler SJ, Stiermaier T, Eitel C, Metzler B, S de W, Fuernau G, Desch S, Thiele H, Eitel I.. Relationship between diabetes and ischaemic injury among patients with revascularized ST-elevation myocardial infarction. Diabetes Obes Metab 2017;19:1706–1713.|||Jensen CJ, Eberle HC, Nassenstein K, Schlosser T, Farazandeh M, Naber CK, Sabin GV, Bruder O.. Impact of hyperglycemia at admission in patients with acute ST-segment elevation myocardial infarction as assessed by contrast-enhanced MRI. Clin Res Cardiol 2011;100:649–659.|||Reinstadler SJ, Stiermaier T, Eitel C, Saad M, Metzler B, Waha S, De Fuernau G, Desch S, Thiele H, Eitel I.. Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction. J Cardiovasc Magn Reson 2016;18:1–8.|||Carrick D, Haig C, Maznyczka AM, Carberry J, Mangion K, Ahmed N, May VTY, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Hood S, Watkins S, Davie A, Mahrous A, Mordi I, Ford I, Radjenovic A, Welsh P, Sattar N, Wetherall K, Oldroyd KG, Berry C.. Hypertension, microvascular pathology, and prognosis after an acute myocardial infarction. Hypertension 2018;72:720–730.|||Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, Inoue K, Fujii K.. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006;27:534–539.|||Reindl M, Reinstadler SJ, Feistritzer HJ, Theurl M, Basic D, Eigler C, Holzknecht M, Mair J, Mayr A, Klug G, Metzler B.. Relation of low-density lipoprotein cholesterol with microvascular injury and clinical outcome in revascularized ST-elevation myocardial infarction. J Am Heart Assoc 2017;6:1–8.|||Symons R, Masci PG, Francone M, Claus P, Barison A, Carbone I, Agati L, Galea N, Janssens S, Bogaert J.. Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker’s paradox revisited. Eur Heart J 2016;37:2756–2764.|||Reinstadler SJ, Eitel C, Fuernau G, de Waha S, Desch S, Mende M, Metzler B, Schuler G, Thiele H, Eitel I.. Association of smoking with myocardial injury and clinical outcome in patients undergoing mechanical reperfusion for ST-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging 2017;18:39–45.|||Haig C, Carrick D, Carberry J, Mangion K, Maznyczka A, Wetherall K, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Hood S, Watkins S, Davie A, Mahrous A, Mordi I, Ahmed N, Teng Yue May V, Ford I, Radjenovic A, Welsh P, Sattar N, Oldroyd KG, Berry C.. Current smoking and prognosis after acute ST-segment elevation myocardial infarction: new pathophysiological insights. JACC Cardiovasc Imaging 2019;12:993–1003.|||Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S.. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017;376:1407–1418.|||Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, Dorbala S, Blankstein R, Di Carli MF.. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012;126:1858–1868.|||Carli MF, Di Janisse J, Grunberger G, Ager J.. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003;41:1387–1393.|||Liu Z. Insulin at physiological concentrations increases microvascular perfusion in human myocardium. Am J Physiol Metab 2007;293:E1250–E1255.|||Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy M, Simonson DC, Creager MA.. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695–1701.|||Ammar RF, Gutterman DD, Brooks LA, Dellsperger KC.. Impaired dilation of coronary arterioles during increases in myocardial O2 consumption with hyperglycemia. Am J Physiol Metab 2017;279:E868–E874.|||Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, Hughes TM, Craft S, Freedman BI, Bowden DW, Vinik AI, Casellini CM.. Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab 2017;102:4343–4410.|||Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, Yellon DM.. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008;103:274–284.|||Paiva M, Riksen NP, Davidson SM, Hausenloy DJ, Monteiro P, Gonçalves L, Providência L, Rongen GA, Smits P, Mocanu MM, Yellon DM.. prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009;53:373–378.|||Paiva MA, Gonçalves LM, Providência LA, Davidson SM, Yellon DM, Mocanu MM.. Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther 2010;24:25–32.|||Calvert JW, Gundewar S, Jha S, Greer JJM, Bestermann WH, Tian R, Lefer DJ.. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008;57:696–705.|||Gundewar S, Calvert J, Jha S, Toedt-Pingel I, Ji S, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, Lefer D.. Activation of AMPK by metformin improves left ventricular function and survival in heart failure. Circ Res 2009;104:403–4011.|||Techiryan G, Weil BR, Palka BA, Canty JM.. Effect of intracoronary metformin on myocardial infarct size in Swine. Circ Res 2018;123:986–995.|||Díaz R, Goyal A, Mehta S, Afzal R, Xavier D, Pais P, Chrolavicius S, Zhu J, Kazmi K, Liu L, Budaj A, Zubaid M, Avezum A, Ruda M, Yusuf S.. Glucose-insulin-potassium therapy myocardial infarction. JAMA 2007;298:2399–2405.|||Sonne DP, Engstrøm T, Treiman M.. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243–249.|||Timmers L, Henriques JPS, Kleijn DPV, de DeVries JH, Kemperman H, Steendijk P, Verlaan CWJ, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE.. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501–510.|||Chang G, Zhang D, Yu H, Zhang P, Wang Y, Zheng A, Qin S.. Cardioprotective effects of exenatide against oxidative stress-induced injury. Int J Mol Med 2013;32:1011–1020.|||Scholte M, Timmers L, Bernink FJ, Denham RN, Beek AM, Kamp O, Diamant M, Horrevoets AJ, Niessen HW, Chen WJ, van Rossum AC, van Royen N, Doevendans PA, Appelman Y.. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial. Trials 2011;12:240..|||Bernink FJP, Timmers L, Diamant M, Scholte M, Beek AM, Kamp O, Marques KMJ, Denham RN, Chen WJY, Doevendans PA, Rossum AC, Van Royen N, Van Horrevoets AJG, Appelman Y.. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study. Int J Cardiol 2013;167:289–290.|||Roos ST, Timmers L, Biesbroek PS, Nijveldt R, Kamp O, Rossum AC, van Hout GPJ, van Stella PR, Doevendans PA, Knaapen P, Velthuis BK, Royen N, van Voskuil M, Nap A, Appelman Y.. No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. Int J Cardiol 2016;220:809–814.|||Lewington S, Clarke R, Qizilbash N, Peto R, Collins R.. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903..|||Panza JA, Quyyumi AA, Brush JE, Epstein SE.. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22–27.|||Brush JE, Faxon DP, Salmon S, Jacobs AK, Ryan TJ.. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992;19:809–815.|||Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA.. Role of endothelium-derived nitric oxide in the abnormal endothelium- dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468–1474.|||Quyyumi AA, Mulcahy D, Andrews NP, Husain S, Panza JA, Cannon RO.. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. Circulation 1997;95:104–110.|||Golino P, Maroko PR, Carew TE.. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation 1987;75:292–298.|||Ko YG, Won H, Shin DH, Kim JS, Kim BK, Choi D, Hong MK, Bae JH, Lee S, Lim DS, Jang Y.. Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study). Am J Cardiol 2014;114:29–35.|||Post S, Post MC, Branden BJ, Van Den Eefting FD, Goumans MJ, Stella PR, Es HW, Van Wildbergh TX, Rensing BJ, Doevendans PA.. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial. Catheter Cardiovasc Interv 2012;80:756–765.|||Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, SchäFers KP, LüScher TF, Camici PG, Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 2000;102:1233–1238.|||Zeiher AM, SchäChinger V, Minners J.. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995;92:1094–1100.|||Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KAA, Boon NA, Webb DJ.. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999;99:1411–1415.|||Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, Collet J-P, Kristensen SD, Aboyans V, Baumbach A, Bugiardini R, Coman IM, Delgado V, Fitzsimons D, Gaemperli O, Gershlick AH, Gielen S, Harjola V-P, Katus HA, Knuuti J, Kolh P, Leclercq C, Lip GYH, Morais J, Neskovic AN, Neumann F-J, Niessner A, Piepoli MF, Richter DJ, Shlyakhto E, Simpson IA, Steg PG, Terkelsen CJ, Thygesen K, Windecker S, Zamorano JL, Zeymer U, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J-P, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Chettibi M, Hayrapetyan HG, Metzler B, Ibrahimov F, Sujayeva V, Beauloye C, Dizdarevic-Hudic L, Karamfiloff K, Skoric B, Antoniades L, Tousek P, Terkelsen PJ, Shaheen SM, Marandi T, Niemelä M, Kedev S, Gilard M, Aladashvili A, Elsaesser A, Kanakakis IG, Merkely B, Gudnason T, Iakobishvili Z, Bolognese L, Berkinbayev S, Bajraktari G, Beishenkulov M, Zake I, Lamin HB, Gustiene O, Pereira B, Xuereb RG, Ztot S, Juliebø V, Legutko J, Timóteo AT, Tatu-Chiţoiu G, Yakovlev A, Bertelli L, Nedeljkovic M, Studenčan M, Bunc M, García de Castro AM, Petursson P, Jeger R, Mourali MS, Yildirir A, Parkhomenko A, Gale CP.. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018;39:119–177.|||Francone M, Bucciarelli-Ducci C, Carbone I, Canali E, Scardala R, Calabrese FA, Sardella G, Mancone M, Catalano C, Fedele F, Passariello R, Bogaert J, Agati L.. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with st-segment elevation myocardial infarction. Insight from cardiovascular magnetic resonance. J Am Coll Cardiol 2009;54:2145–2153.|||Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA, Sutton A, De Belder MA.. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 2006;92:1278–1284.|||Su Q, Nyi T, Li L.. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev 2015;5:CD009503.|||Nazir SA, McCann GP, Greenwood JP, Kunadian V, Khan JN, Mahmoud IZ, Blackman DJ, Been M, Abrams KR, Shipley L, Wilcox R, Adgey AAJ, Gershlick AH.. Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. Eur Heart J 2016;37:1910–1919.|||Kelbæk H, Høfsten DE, Køber L, Helqvist S, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Backer O, De Bang LE, Kofoed KF, Lønborg J, Ahtarovski K, Vejlstrup N, Bøtker HE, Terkelsen CJ, Christiansen EH, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Jensen LO, Clemmensen P, Grande P, Madsen JK, Torp-Pedersen C, Engstrøm T.. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet 2016;387:2199–2206.|||Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, Hood S, Owens C, Watkins S, Layland J, Lindsay M, Peat E, Rae A, Behan M, Sood A, Hillis WS, Mordi I, Mahrous A, Ahmed N, Wilson R, Lasalle L, Généreux P, Ford I, Berry C.. A randomized trial of deferred stenting versus immediate stenting to prevent No- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol 2014;63:2088–2098.|||Belle L, Motreff P, Mangin L, Rangé G, Marcaggi X, Marie A, Ferrier N, Dubreuil O, Zemour G, Souteyrand G, Caussin C, Amabile N, Isaaz K, Dauphin R, Koning R, Robin C, Faurie B, Bonello L, Champin S, Delhaye C, Cuilleret F, Mewton N, Genty C, Viallon M, Bosson JL, Croisille P.. Comparison of immediate with delayed stenting using the minimalist immediate mechanical intervention approach in acute ST-segment-elevation myocardial infarction: the MIMI study. Circ Cardiovasc Interv 2016;9:e003388.|||Kim JS, Lee HJ, Yu CW, Kim YM, Hong SJ, Park JH, Choi RK, Choi YJ, Park JS, Kim TH, Jang HJ, Joo HJ, Cho SA, Ro YM, Lim DS.. INNOVATION study (Impact of Immediate Stent Implantation Versus Deferred Stent Implantation on Infarct Size and Microvascular Perfusion in Patients With ST-Segment-Elevation Myocardial Infarction). Circ Cardiovasc Interv 2016;9:e004101..|||Sadamatsu K, Yoshida K, Yoshidomi Y, Tokunou T, Tanaka H, Tashiro H, Shikada T, Iwamoto K, Morishige K.. Acute effects of isosorbide dinitrate and nicorandil on the coronary slow flow phenomenon. Am J Cardiovasc Drugs 2010;10:203–208.|||Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, Dambrink J-HE, Escalera N, Lipsic E, Albarran A, Fernández-Ortiz A, Fernández-Avilés F, Goicolea J, Botas J, Remkes W, Hernandez-Jaras V, Kedhi E, Zamorano JL, Navarro F, Alfonso F, García-Lledó A, Alonso J, van Leeuwen M, Nijveldt R, Postma S, Kolkman E, Gosselink M, de Smet B, Rasoul S, Piek JJ, Fuster V, van't Hof AWJ.. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67:2705–2715.|||Ibanez B, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, Fernández-Ortiz A, García-Ruiz JM, García-Álvarez A, Iñiguez A, Jiménez-Borreguero J, López-Romero P, Fernández-Jiménez R, Goicolea J, Ruiz-Mateos B, Bastante T, Arias M, Iglesias-Vázquez JA, Rodriguez MD, Escalera N, Acebal C, Cabrera JA, Valenciano J, Pérez de Prado A, Fernández-Campos MJ, Casado I, García-Rubira JC, García-Prieto J, Sanz-Rosa D, Cuellas C, Hernández-Antolín R, Albarrán A, Fernández-Vázquez F, de la Torre-Hernández JM, Pocock S, Sanz G, Fuster V.. Effect of early metoprolol on infarct size in ST-segment–elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Circulation 2013;128:1495–1503.|||Pizarro G, Fernández-Friera L, Fuster V, Fernández-Jiménez R, García-Ruiz JM, García-Álvarez A, Mateos A, Barreiro MV, Escalera N, Rodriguez MD, de Miguel A, García-Lunar I, Parra-Fuertes JJ, Sánchez-González J, Pardillos L, Nieto B, Jiménez A, Abejón R, Bastante T, Martínez de Vega V, Cabrera JA, López-Melgar B, Guzman G, García-Prieto J, Mirelis JG, Zamorano JL, Albarrán A, Goicolea J, Escaned J, Pocock S, Iñiguez A, Fernández-Ortiz A, Sánchez-Brunete V, Macaya C, Ibanez B.. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the Metocard-CNIC trial (Effect of Metoprolol in Cardioprotection during an Acute Myocardial Infarction). J Am Coll Cardiol 2014;63:2356–2362.|||García-Prieto J, Villena-Gutiérrez R, Gómez M, Bernardo E, Pun-García A, García-Lunar I, Crainiciuc G, Fernández-Jiménez R, Sreeramkumar V, Bourio-Martínez R, García-Ruiz JM, Valle AS, Del Sanz-Rosa D, Pizarro G, Fernández-Ortiz A, Hidalgo A, Fuster V, Ibanez B.. Neutrophil stunning by metoprolol reduces infarct size. Nat Commun 2017;8:14780.|||Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di LF, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D.. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol 2016;111:70.|||Davidson SM, Ferdinandy P, Andreadou I, Bøtker HE, Heusch G, Ibáñez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ, Garcia-Dorado D.. Strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol 2019;73:89–99.|||Cung T-T, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, Bonnefoy-Cudraz E, Guérin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge M, Aupetit J-F, Jouve B, Motreff P, Tron C, Labeque J-N, Steg PG, Cottin Y, Range G, Clerc J, Claeys MJ, Coussement P, Prunier F, Moulin F, Roth O, Belle L, Dubois P, Barragan P, Gilard M, Piot C, Colin P, De Poli F, Morice M-C, Ider O, Dubois-Randé J-L, Unterseeh T, Le Breton H, Béard T, Blanchard D, Grollier G, Malquarti V, Staat P, Sudre A, Elmer E, Hansson MJ, Bergerot C, Boussaha I, Jossan C, Derumeaux G, Mewton N, Ovize M.. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 2015;373:1021–1031.|||Atar D, Arheden H, Berdeaux A, Bonnet J-L, Carlsson M, Clemmensen P, Cuvier V, Danchin N, Dubois-Rande J-L, Engblom H, Erlinge D, Firat H, Halvorsen S, Hansen HS, Hauke W, Heiberg E, Koul S, Larsen A-I, Le Corvoisier P, Nordrehaug JE, Paganelli F, Pruss RM, Rousseau H, Schaller S, Sonou G, Tuseth V, Veys J, Vicaut E, Jensen SE.. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur Heart J 2015;36:112–119.|||Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Clemmensen P, Holmvang L, Jørgensen E, Pedersen F, Saunamaki K, Ravkilde J, Tilsted H-H, Villadsen A, Aarøe J, Jensen SE, Raungaard B, Bøtker HE, Terkelsen CJ, Maeng M, Kaltoft A, Krusell LR, Jensen LO, Veien KT, Kofoed KF, Torp-Pedersen C, Kyhl K, Nepper-Christensen L, Treiman M, Vejlstrup N, Ahtarovski K, Lønborg J, Køber L.. Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction: a randomized clinical trial. JAMA Cardiol 2017;2:490–497.|||Sluijter JPG, Davidson SM, Boulanger CM, Buzás EI, de Kleijn DPV, Engel FB, Giricz Z, Hausenloy DJ, Kishore R, Lecour S, Leor J, Madonna R, Perrino C, Prunier F, Sahoo S, Schiffelers RM, Schulz R, Van Laake LW, Ytrehus K, Ferdinandy P.. Extracellular vesicles in diagnostics and therapy of the ischaemic heart : position paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2018;114:19–34.|||Loyer X, Vion A, Tedgui A, Boulanger CM, Loyer X, Vion A, Tedgui A, Boulanger CM.. Microvesicles as cell–cell messengers in cardiovascular diseases. Circ Res 2014;114:345–353.|||Lawson C, Vicencio JM, Yellon DM, Davidson SM.. Microvesicles and exosomes : new players in metabolic and cardiovascular disease. J Endocrinol 2016;228:57–71.|||Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, Mallat Z.. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001;102:2649–2652.|||Porto I, Biasucci LM, Maria GL, De Leone AM, Niccoli G, Burzotta F, Trani C, Tritarelli A, Vergallo R, Liuzzo G, Crea F.. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur Heart J 2012;33:2928–2938.|||Giricz Z, Varga ZV, Baranyai T, Sipos P, Pálóczi K, Kittel Á, Buzás E, Ferdinandy P.. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. J Mol Cell Cardiol 2014;68:75–78.|||Ma F, Liu H, Shen Y, Zhang Y, Pan S.. Platelet-derived microvesicles are involved in cardio-protective effects of remote preconditioning. Int J Clin Exp Pathol 2015;8:10832–10839.|||Liu M, Wang Y, Zhu Q, Zhao J, Wang Y, Shang M, Liu M, Wu Y, Song J, Liu Y.. Protective effects of circulating microvesicles derived from ischemic preconditioning on myocardial ischemia/reperfusion injury in rats by inhibiting endoplasmic reticulum stress. Apoptosis 2018;23:436–448.|||Niccoli G, Montone RA, Ibanez B, Thiele H, Crea F, Heusch G, Bulluck H, Hausenloy DJ, Berry C, Stiermaier T, Camici PG, Eitel I.. Optimized treatment of ST-elevation myocardial infarction. Circ Res 2019;125:245–258.